About

This clinical guide explains the key parameters and outputs related to the Pretomanid Dose Calculator for BPaL/BPaM Regimens. It provides context on standard dosing, administration, and critical safety considerations that inform the calculator's recommendations. Use this information to better understand the tool's logic, which is based on official prescribing information and global guidelines.

Outputs

After processing the inputs, the tool provides the following critical information:

• Recommended Dose: The standard dose of Pretomanid (200 mg daily) as part of the BPaL regimen.
• Safety Alerts & Warnings: Highlights contraindications and cautions. This includes high-risk scenarios like severe hepatic impairment (Child-Pugh C) or co-administration with strong CYP3A4 inducers (e.g., rifampin).
• Clinical Monitoring Parameters: A checklist of essential monitoring for patient safety, including tests for hepatotoxicity, myelosuppression, neuropathy, QT prolongation, and lactic acidosis.

How to Use

To use the calculator effectively, a healthcare professional must input the following patient-specific data:

1. Hepatic Function: Select the patient's liver function status based on the Child-Pugh classification (Normal, Child-Pugh A, B, or C). This is a critical factor, as Pretomanid is not recommended for patients with severe (Child-Pugh C) impairment.
2. Concomitant Medications: Select any co-administered drugs that are known strong or moderate CYP3A4 inducers or strong CYP3A4 inhibitors. These medications can significantly alter Pretomanid exposure, affecting efficacy and safety.

Dosing Overview

The standard adult dosing schedule for Pretomanid is 200 mg administered orally, once daily, for 26 weeks. It must be administered as part of a combination regimen with bedaquiline and linezolid (BPaL).

Administration: Pretomanid tablets should be taken with food and a glass of water to optimize absorption. The tablet should be swallowed whole and not crushed, split, or chewed.

Switching

Pretomanid is a component of a specific, highly-regulated treatment regimen (BPaL/BPaM) for specific types of drug-resistant tuberculosis. Any modification, interruption, or switching of components within this regimen should not be done without consulting a specialist in tuberculosis treatment. Unplanned changes can lead to treatment failure or the development of further resistance.

Missed Dose

If a dose of Pretomanid is missed, the patient should take the missed dose as soon as they remember. However, if it is almost time for the next scheduled dose, they should skip the missed dose and resume their normal dosing schedule. Patients should be instructed not to take two doses at the same time to make up for a missed one.

Safety Alerts

The following are critical safety considerations based on the Pretomanid prescribing information:

• Hepatic Impairment: Pretomanid is not recommended in patients with severe hepatic impairment (Child-Pugh C). Use with caution in patients with moderate impairment (Child-Pugh B).
• Drug-Drug Interactions (DDI): Co-administration with strong CYP3A4 inducers (e.g., rifampin, efavirenz) is contraindicated as it can drastically reduce Pretomanid levels and efficacy. Use with caution alongside moderate inducers or strong inhibitors of CYP3A4.
• Hepatotoxicity: Liver-related adverse reactions have been reported. Liver function tests should be monitored at baseline and regularly throughout treatment.
• Neuropathy & Myelosuppression: When used with linezolid, there is an increased risk of peripheral and optic neuropathy and myelosuppression. Regular monitoring is essential.
• QT Prolongation: Pretomanid can prolong the QT interval. An ECG should be obtained at baseline, especially if the patient has other risk factors or is taking other QT-prolonging drugs.

Frequently Asked Questions (FAQ)

1. What is the recommended dose of Pretomanid for adults?
The standard dose is 200 mg orally once daily for 26 weeks, taken with food as part of the BPaL regimen.

2. Can Pretomanid be used in a patient with severe liver disease (Child-Pugh C)?
No, the calculator will issue a high alert. Pretomanid is not recommended for patients with severe hepatic impairment as its safety has not been established in this group.

3. Why is co-administration with rifampin contraindicated?
Rifampin is a strong CYP3A4 inducer, which significantly accelerates the metabolism of Pretomanid. This leads to a sharp decrease in Pretomanid plasma concentration and a high risk of treatment failure.

4. Does renal impairment affect the Pretomanid dose?
No, dose adjustment is not required for any degree of renal impairment, including for patients on hemodialysis.

5. What should I do if a patient is taking St. John's Wort?
St. John's Wort is a strong CYP3A4 inducer and its use is contraindicated with Pretomanid. The patient should be advised to discontinue it.

6. Is it safe to use Pretomanid with ketoconazole?
Ketoconazole is a strong CYP3A4 inhibitor. This combination may increase Pretomanid exposure and the risk of side effects. The calculator issues a caution, and close clinical monitoring for toxicity is recommended.

7. What does BPaL stand for?
BPaL stands for the three-drug regimen: (B)edaquiline, (P)retomanid, and (L)inezolid.

8. How should Pretomanid be administered?
It should be taken orally with food and a glass of water to improve absorption.

9. What are the most important parameters to monitor during treatment?
Key monitoring includes liver function tests (ALT, AST, bilirubin), complete blood counts, and regular checks for symptoms of peripheral neuropathy and vision changes, especially when linezolid is part of the regimen.

10. Does the calculator account for pediatric patients?
No, this calculator and the standard dosing are intended for adult patients only.